On Tuesday, Shares of Vale SA (ADR) (NYSE:VALE), added 2.82% and closed at $5.84 in the last trading session. VALE stock opened its last trade at $5.82 and after floating in a range of $5.72 to $5.90. The company’s Market capitalization is $30.37 Billion with the total Outstanding Shares of 3.19 million. During the 52-week trading session the minimum price at which share price traded, registered at $2.13 and reached to max level of $6.26.The Earnings per Share of the company stands at $-1.51. Vale S.A., together with its auxiliaries, engages in the research, production, and sale of iron ore and pellets, nickel, fertilizer, copper, coal, manganese, ferroalloys, cobalt, platinum group metals, and precious metals in Brazil and internationally. Its Bulk Material segment produces and extracts iron ore and pellet. This segment is also involved in the production and extraction of manganese, ferroalloys, and others ferrous products and services; and extraction of coal, in addition to in the provision of railroad, port, and terminal logistics services. The companys Base Metals segment produces and extracts non-ferrous minerals, counting nickel and copper. Its Fertilizers segment provides a group of nutrients, such as potash, phosphates, and nitrogen.
Shares of Mylan NV (NASDAQ:MYL), added 2.61% and closed at $37.39 in the last trading session. MYL stock opened its last trade at $36.95 and after floating in a range of $36.69 to $37.39. The company’s Market capitalization is $20.00 Billion with the total Outstanding Shares of 534.91 million. During the 52-week trading session the minimum price at which share price traded, registered at $35.58 and reached to max level of $55.51.The Earnings per Share of the company stands at $1.57. Glancy Prongay & Murray LLP (“GPM”) declares an investigation on behalf of Mylan N.V. (“Mylan” or the “Company”) (NASDAQ: MYL) shareholders concerning the Company and its officers’ possible violations of federal securities laws.
Mylan, together with its auxiliaries, develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals worldwide.
Specifically, the investigation concerns a letter issued on October 5, 2016 from the Centers for Medicare and Medicaid Services (“CMS”) asserting that Mylan had overcharged the U.S. Medicaid health program for the Company’s EpiPen shot, despite being told that Mylan needed to provide larger discounts under the law. The CMS letter stated that from 2011 to 2015, the U.S. Medicaid health program spent about $797 million on EpiPens, counting rebates of roughly 13%, rather than the discount of 23.1% that the U.S. should have received. The letter claimed that the government had “expressly told Mylan that the [EpiPen] product is incorrectly classified.”